Part II: Management of resistance to imatinib in chronic myeloid leukaemia-Reference-Cited by-同舟云学术

Part II: Management of resistance to imatinib in chronic myeloid leukaemia

Published:2007-12 Issue:12 Volume:8 Page:1116-1128
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Apperley Jane F

Publisher

Elsevier BV

Subject

Oncology

Reference85 articles.

1. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogenic bone marrow transplantation in treating the chronic phase of chronic myeloid leukaemia: developed for the American Society of Hematology;Silver;Blood,1999

2. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

4. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays;Lombardo;J Med Chem,2004

5. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction;Copland;Blood,2006

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Derivatives of 1-(3-Methyl-1-Benzofuran-2-yl)Ethan-1-one: Synthesis and Preliminary Studies of Biological Activity;International Journal of Molecular Sciences;2024-02-07

2. Atypical N-Alkyl to N-Noralkoxy Switch in a Dual cSRC/BCR-ABL1 Kinase Inhibitor Improves Drug Efflux and hERG Affinity;ACS Medicinal Chemistry Letters;2023-12-05

3. A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-04

4. Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia;Medicinal Chemistry Research;2023-02-02

5. The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug;Journal of Medicinal Chemistry;2022-05-24